Ki-67在侵袭性脑膜瘤的表达与意义

目的探讨Ki-67表达水平与脑膜瘤侵袭性的关系。方法回顾性分析68例脑膜瘤病例资料,根据肿瘤侵袭性与否,分为侵袭组（n=18）和非侵袭组（n=50）,测定Ki-67的表达水平,并进行统计学分析。结果男性病人中侵袭性脑膜瘤的发生率（41.7%）明显高于女性（18.2%）（P〈0.05）。不同病理等级,侵袭性脑膜瘤的发生率有明显差别（P〈0.05）。不同年龄段及病理类型,侵袭性脑膜瘤发生率无明显差别（P〉0.05）。脑膜瘤侵袭性或性别,与Ki-67表达水平无明显相关性（P〉0.05）。病理等级和Ki-67表达水平有明显相关性（P〈0.05）。结论 Ki-67表达水平主要与病理等级有关。在相同病理等级脑膜瘤中,Ki-67表达水平与脑膜瘤侵袭性无明显相关性。     

Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II

Simpson grading of resection has been used as a predictor of intracranial meningioma (IM) recurrence. Histopathological findings, like the Ki-67/MIB-1 labeling index, may be useful in the assessment risk of recurrence. Our objective was to analyze the predictive value of meningioma recurrence using both parameters. We retrospectively studied 322 consecutive patients with histopathological diagnosis of IM WHO grade I and 43 patients with IM WHO grade II in a 13-year period. Multivariate survival analysis was performed. In the WHO grade I IM group, recurrence was observed in 28 patients (8.69%). The Cox regression model for WHO grade I IM, provided a significative hazard ratio (HR) for Ki-67/MIB-1 index ≥3 (HR = 36.35, p < 0.001) and Simpson’s grading resection, grade II (HR = 2.03, p = 0.045), grade III (HR = 3.41, p = 0.034) and grade IV (HR = 19.75, p ≥ 0.001). In the WHO grade II IM group, recurrence was observed in 10 patients (23.25%). The Cox regression model for WHO grade II IM, provided a significative hazard ratio (HR) for Ki-67/MIB-1 index ≥3% (HR = 1.66, p < 0.001) and Simpson’s grading resection grade III (HR = 3.96, p = 0.027). The Kaplan–Meier survival curve showed a similar distribution of survival between WHO grade I IM with Ki-67/MIB-1 ≥3% and WHO grade II IM. In WHO grade I meningiomas, the Ki-67/MIB-1 index and Simpson grading were both independent predictors of recurrence. A similar management protocol should be advisable for WHO grade I with Ki-67/MIB-1 ≥3% and WHO grade II meningiomas.     

Outcome of resection of WHO Grade II meningioma and correlation of pathological and radiological predictive factors for recurrence

This study investigated whether extent of surgical resection (Simpson and Shinshu grade) along with pathological and radiological factors influence the tumor control and recurrence-free survival (RFS) of patients with World Health Organization (WHO) grade II meningiomas. The clinical, radiological and surgical notes on the 59 patients with WHO grade II meningioma managed at our institution over 20 years were retrospectively reviewed. In this study, median survival time was 41 months. The overall recurrence rate in Simpson grades I and II resection was 31%. In grades III and IV, the overall recurrence rate was 73%, and this high recurrence rate in these groups was confined within 5 years. In Cox regression analysis, combined data of grades (I and II)/complete resection showed a significant difference in RFS compared to grades (III and IV)/subtotal resection (p = 0.0001). A similar trend of RFS (p = 0.0001) was observed with the Shinshu grading system of resection. In addition, a Ki-67% marker for proliferation less than 15% (p = 0.029), absence of certain radiological features including heterogeneous enhancement, cyst formation and peritumoral edema (p = 0.006), and repeat surgery for recurrent meningioma was associated with better survival (p = 0.014). However, radiosurgery did not have a beneficial role in the treatment of recurrence of atypical meningioma. The Simpson grading system is the primary predictor of recurrence of WHO grade II meningioma after resection. In addition, certain pathological and radiological features need to be considered as possible factors of recurrence after resection. Lastly, depending on the likely risks and surgical morbidity, repeat surgical resection should be performed for recurrent atypical meningioma.     

The double immunostaining of CD133 and Ki-67 favours a significant co-localization pattern in fibroblastic subtype of meningiomas

BACKGROUND AND PURPOSE : A unique molecular and/or cellular marker for meningiomas, the most common intracranial tumours, has not been identified yet. MATERIAL AND METHODS: We investigated the co-localization fraction of CD133/Ki-67 in meningioma tissue array slide composed of 80 meningioma tissue samples of various histological variants. CD133 - a cell membrane stem cell marker - was previously proved to be associated with the initiation and progression of intracerebral gliomas and medulloblastomas. RESULTS : Immunohistochemical co-localization of CD133/Ki-67 was significantly higher in fibroblastic variant than in meningothelial and transitional subtypes. However, since there were only 3 atypical and 1 malignant meningioma spots in the tumour tissue array slide, it is difficult to draw a firm conclusion regarding the actual co-localization percentage and persistence of CD133/Ki-67 in atypical and malignant meningiomas. CONCLUSIONS : Far higher co-staining percentage of CD133/ Ki-67 in fibroblastic meningioma samples compared to meningothelial subtype, a histological meningioma variant, architectonically resembling the non-neoplastic meningeal cells, gave us the impression that CD133 may play a role in the formation and progression of fibroblastic meningioma variants. The persistency and the validity of this finding need to be verified by further histopathological and molecular research in order to clarify the possible role of CD133 in meningiogenesis.     

血管内皮生长因子、细胞周期相关核抗原Ki-67抗体和p53表达水平与脑膜瘤术后瘤周水肿的相关性研究

目的 探讨血管内皮生长因子(Vascular endothelial growth factor,VEGF)、细胞周期相关核抗原Ki-67抗体和p53的表达水平对脑膜瘤术后瘤周水肿(Pedtumoral brain edema,PTBE)的影响.方法 选取2007年1月-2016年7月于本院就诊的脑膜瘤手术患者159例...     

非典型性脑膜瘤及恶性脑膜瘤预后的相关因素分析

目的总结非典型性脑膜瘤(atypical meningioma,AM)及恶性脑膜瘤治疗中的经验,分析与其预后相关的主要临床因素。方法整理2004-10—2014-02就诊于我院的96例非典型性及恶性脑膜瘤患者的相关资料,包括性别、年龄等一般资料及远期生活质量评分(Karnofsky performance scale score,KPS评分)、生存期(overall survival,OS)、无进展生存期(progressionfree survival,PFS)、病理结果等。结果 96例患者中68例非典型性脑膜瘤和28例恶性脑膜瘤。80.9%非典型性脑膜瘤患者和67.9%恶性脑膜瘤患者手术达到SimpsonⅠ~Ⅲ级切除;31例(44.1%)非典型性脑膜瘤患者和19例(71.4%)恶性脑膜瘤患者术后进行放疗。中位随访时间25个月,恶性脑膜瘤患者总生存期较非典型性脑膜瘤更短,手术结合术后放疗的无进展生存期长于单纯手术治疗。结论对于非典型性脑膜瘤及恶性脑膜瘤,手术全切肿瘤非常重要,且术后放疗可延长患者生存期。     

大脑镰旁脑膜瘤显微外科手术治疗

目的探讨大脑镰旁脑膜瘤的手术方法和技巧。方法对16例经手术治疗的大脑镰旁脑膜瘤的临床治疗进行回顾性分析。结果手术全切肿瘤13例,其中SimpsonI级切除9例,SimpsonlI级切除4例,其余3例SimpsonIII级切除。术后随访6—72月,2例复发,无手术死亡。结论大脑镰旁脑膜瘤手术治疗力争达到全切除,有效地控制术中出血、保护并妥善处理好重要回流静脉是确保手术成功的关键。     

人脑胶质瘤中CD15、Ki-67的表达及其临床意义

目的研究细胞粘附分子CD15及Ki-67抗原在人脑胶质瘤中的表达及其临床意义。方法应用免疫组化S-P法检测例正常脑组织和858例人脑胶质瘤组织中CD15和Ki-67的表达。结果CD15和Ki-67在正常脑组织中均不表达,而在各级别的人脑胶质瘤中均有表达差异极显著,(P<0.01)。CD15和Ki-67的表达在高级别胶质瘤中均显著高于低级别胶质瘤(P<0.01),且CD15和Ki-67的表达呈显著正相关(P<0.05,r=0.462)。结论Ki-67可以作为评估胶质瘤细胞增殖的良好指标,CD15和Ki-67的表达可为判断胶质瘤的恶性程度和临床病理分级提供有意义的依据。     

Clinical Features and Treatment Outcome of Chordoid Meningiomas in a Single Institute

Objective

Meningioma is the second most common primary central nervous system neoplasm. In contrast, chordoid meningioma is rare; due to the paucity of cases, little is known about its clinical features or treatment outcomes. The objectives of this study were to describe the clinical characteristics and outcomes for patients with chordoid meningioma.

Methods

In total, 16 patients, with newly diagnosed chordoid meningioma who underwent surgical excision between 1999 and 2012 were included. We retrospectively evaluated the medical records, radiological findings, and pathological findings. The median follow-up period was 56.5 (range, 3-170) months. The MIB-1 labeling index ranged from 1 to 26.60% (median, 5.04).

Results

Simpson grade I, II, and III resections were performed in four, nine, and three patients, respectively. The overall recurrence rate was 37.5%. Overall progression-free survival (PFS) after resection was 94.7 months (95% CI=62.9-126.6). Of the 4 patients with Simpson grade I resection, recurrence occurred in one patient. Among the Simpson grade II and III resection groups, eight patients underwent adjuvant radiation therapy and they showed significantly longer PFS (121 months, 95% CI=82.1-159.9) than the patients who underwent surgery alone (40.5 months, 95% CI=9.6-71.3) by the log-rank test (p<0.05).

Conclusion

Chordoid meningiomas are difficult to manage and have a high rate of recurrence. Complete resection of the tumor is a key determinant of better outcomes. Adjuvant radiation therapy is recommended, eparticulary when Simpson grade I resection was not achieved.     

Evaluation of P57, P53 and Ki67 Expression in Meningiomas

ObjectiveWe conducted this study with the aim of predicting the biological behavior of meningiomas, and determining the benefits of associating histological subtype and grade with the expression of proliferative markers and tumor suppressor proteins. MethodsThe study included 29 patients with primary intracranial and intraspinal meningioma diagnosed in the pathology laboratory of Konya City Hospital between January 2014 and December 2020. Clinicopathological characteristics of the patients including parameters such as age and gender were obtained from the hospital records. Histopathological findings were obtained by re-evaluating the preparations stained with Hematoxylin-Eosin, which were extracted from the archive, and by evaluating new sections obtained from paraffin blocks of patients stained with Ki67, p53, and p57 immunohistochemical stains. ResultsA moderate correlation was found between tumor size and Ki67 proliferation index (PI) (p=0.003, r=0.530). There was no significant difference between grade I and grade II tumors in terms of p53 (p=0.184) and p57 (p=0.487) expressions. There were higher levels of Ki67 PI in grade II tumors. The histological subtypes of the tumor had no significant difference with Ki67 PI (p=0.018), p53 (p=0.662), and p57 (p=0.368) expressions. ConclusionIn order to obtain more definitive results, there is a need for studies, which are conducted with a greater number of patients and in multiple centers, and in which a long prospective follow-up is planned. The combination of histological, surgical, and imaging markers could make a more sensitive tool for predicting recurrence, and this could also be tested in future studies.     

人脑胶质瘤中Survivin、Ki-67的表达及其临床意义

目的探讨Survivin和Ki-67抗原在人脑胶质瘤中的表达及其临床意义。方法应用免疫组化SP法检测10倒正常脑组织和68例人脑胶质瘤中Survivin和Ki-67的表达。结果Survivin和Ki-67在正常脑组织中均不表达,而在各级别的人脑胶质瘤中均有表达,差异极显著（P％0.01）,Survivin和Ki-67的表达在高级别胶质瘤中显著高于低级别胶质瘤（P％0．01）,且Survivin和Ki-67的表达呈显著正相关（P〈0．05）。结论Ki-67可以作为评估胶质瘤细胞增殖的良好指标,Survivin和Ki-67的表达可以判断胶质瘤的恶性程度,为临床病理分级提供有意义的依据。     

Long-term outcomes of spinal meningioma resection with outer layer of dura preservation technique

Spinal meningioma is a common benign intradural spinal tumor. It has been reported that the local recurrence rate after surgical resection increases with longer follow-up duration. Simpson grade 1 resection could reduce the risk of recurrence, but this procedure needs dural reconstruction, which would cause cerebrospinal fluid (CSF) leakage or iatrogenic spinal cord injury. Saito et al. reported dura preservation technique to reduce the risk of CSF leakage, in which the meningioma together with the inner layer of the dura is removed and the outer layer is preserved for simple dural closure. The long-term outcomes with this technique have never been investigated. In this study, we retrospectively analyzed the data of 38 surgically treated patients (dura preservation technique, 12 patients; Simpson grade 2 resection, 26 patients) to assess the long-term recurrence rate (mean, 121.5 months; range, 60–228 months). The local recurrence rate in the dura preservation group was 8.3% (1 of 12 cases), which was similar to that in Simpson grade 2 resection group (2 of 26 cases [7.7%]). Although this case series did not indicate the significant difference in the recurrence rates between the dura preservation group and Simpson grade 2 group, we consider that this technique still has advantages for surgically less invasiveness in terms of dural reconstruction which is necessary for Simpson grade 1 and higher possibility of complete resection of tumors compared with Simpson grade 2 resection.     

枕骨大孔区脑膜瘤的显微手术治疗

目的 探讨枕骨大孔区脑膜瘤的手术方法及其疗效。方法 回顾性分析2012年1月至2020年11月显微手术治疗的13例枕骨大孔区脑膜瘤的临床资料。结果 7例脑干腹侧肿瘤采用远外侧入路,5例脑干外侧肿瘤采用后正中入路2例、远外侧入路3例,1例脑干背侧肿瘤采用后正中入路。肿瘤全切除12例（Simpson分级Ⅰ级1例,Ⅱ级11例）,部分切除1例（Simpson分级Ⅳ级）。3脑干腹侧肿瘤术后出现并发症,其中1例后组颅神经功能障碍、1例肢体肌力下降,治疗半年恢复正常;1例因脑脊液漏,引发颅内感染、肺部感染、尿路感染以及应激性溃疡而死亡。存活12例术后随访18～120个月,平均（77.31±38.25）个月;1例脑干外侧肿瘤出现脑积水,1例复发,其余10例无复发、正常生活。结论 对枕骨大孔区脑膜瘤,根据肿瘤位置及特点选择合适的手术入路,术中保护好椎动脉、脑干、后组颅神经等重要组织,显微手术可取得良好的疗效。     

血管外膜细胞瘤p53和Ki-67的表达与肿瘤分级和复发的关系

目的 探讨中枢神经系统血管外膜细胞瘤(HPC)中p53及Ki-67的表达与肿瘤的分级和复发的关系. 方法 回顾性分析北京天坛医院自2005年1月采用至2008年1月手术切除治疗的97例中枢神经系统HPC患者的临床资料,HE染色97例FIPC标本并按照WHO标准进行分级;免疫组织化学染色检测并比较不同分级、复发和未复发肿瘤标本中p53和Ki-67的表达.结果 HE染色检测显示HPC分级Ⅱ级74例,Ⅲ级23例;随访结果显示未复发HPC 49例,复发39例;免疫组化检测结果显示Ⅱ级HPC中p53和Ki-67阳性细胞数均明显低于Ⅲ级,未复发病例的Ki-67和p53阳性细胞数均明显低于复发病例,差异均有统计学意义(P<0.05).结论 Ki-67、p53的表达越高,HPC的组织分级越高,复发风险越高,可作为判断HPC患者预后的指标.     

Low recurrence after Simpson grade II resection of spinal benign meningiomas in a single-institute 10-year retrospective study

The objective of this study was to more fully understand the optimal neurosurgical strategy for spinal benign meningiomas from a medium to long-term perspective. This retrospective study included a cohort of 35 patients with a diagnosis of spinal meningioma who were first operated at our institute over the past 10 years and followed-up for at least 2 years after surgery. The inclusion criterion for the study was the pathological diagnosis finally verified as benign meningioma of World Health Organization (WHO) grade 1. The average follow-up duration after surgery was 61.0 months. The location of the spinal meningioma was classified into ventral or dorsal type based on the operative video record and the preoperative MR images. The extent of resection of the spinal meningioma was carefully determined based on the Simpson grade. The average neurological condition was significantly improved at the final follow-up. Simpson grade I or II resection was achieved in 31 of 35 cases (88.6%). No Simpson grade I or II cases showed local recurrence during follow-up. Tumor recurrence was noted in 2 of 4 cases of Simpson grade IV resection. One case has been followed-up without any re-operation because of no neurological deterioration, and the other case underwent stereotactic radiosurgery. This study suggested that meticulous Simpson grade II resection of spinal benign meningiomas of WHO grade 1 may be good enough from a medium to long-term follow-up perspective, though longer follow-up is absolutely necessary.     

Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67

Summary In 30 meningiomas we investigated the proliferation rate of various subtypes with the monoclonal antibody Ki-67. Frozen sections were incubated with Ki-67 antibody using a modified Alkaline Phosphatase anti-Alkaline Phosphatase (APAAP)-technique and evaluation of proliferation rate was done by cell counting. Meningiomas of the meningiotheliomatous, fibrous and angioblastic subtype without atypical histological findings contained 1% or less proliferating cells. In recurent tumors, in transitional and in anaplastic meningiomas there is a marked increase of proliferating cells up to 20%. The distribution of marked cells varies in recurrent tumors and anaplastic meningiomas, and a focal proliferation of tumor cells was seen in meningiomas from transitional type. Immunohistological labelling of proliferating cells in meningiomas may allow a more precise prediction of the proliferation potential of each meningioma.     

Treatment and follow-up results of WHO grade II meningiomas

Meningiomas are the most common primary intracranial tumors. They have three pathologic grades. Surgical resection aiming Simpson I resection is the standard treatment for meningiomas. Radiotherapy and Gamma Knife radiosurgery are the main adjuvant and salvage treatments. Chemotherapy has limited use. Grade II, and III meningiomas have a higher recurrence rate, and adjuvant radiotherapy is usually the standard treatment for grade III meningiomas but there is not a consensus regarding grade II meningiomas. In this paper, we analyzed our meningioma series of 1401 patients and presented the treatment and follow-up results of 170 grade II meningioma cases. The median follow-up of grade II meningiomas was 61 (range = 1–231) months. The mean age of patients was 52.5 ± 15.0 years, 102 of them were female and 68 were male (female/male ratio = 1.5). The median progression-free survival (PFS) of them was 109 months, and the cumulative overall survival (OS) rate was 85% at 10 years. Meningiomas with gross total resection, non-skull base meningiomas, and primary grade II meningiomas had longer PFS with statistical significance, while non-skull base meningiomas, younger group of patients, and primary grade II meningiomas had longer OS with a statistical significance.     

Proliferation and Dna fragmentation in meningioma subtypes

H. Maier, J. Wanschitz, R. Sedivy, K. Rössler, D. Öfner and H. Budka (1997) Neuropathology and Applied Neurobiology 23, 496–506 Proliferation and DNA fragmentation in meningioma subtypes Atypical meningioma has been introduced as tumour subtype of intermediate biological behaviour between classical and malignant meningiomas. To substantiate this three-step scale of malignancy, we assessed the proliferative activity reflected by Ki-67 (MIB1) labelling index (LI) in a series of 89 meningiomas, including 15 classical, 29 atypical, 35 anaplastic tumours, and 10 haemangiopericytomas and papillary meningiomas. The possible correlation of proliferation with the frequency of apoptosis and their relations to BCL-2 immunoexpression was investigated in seven classical, 10 atypical and 10 malignant meningiomas. Apoptosis was demonstrated by evaluation of the frequency of apoptotic figures, by the enzymatic technique of in situ tailing (IST) which stains apoptotic DNA fragments, and by DNA preparation and gel electrophoresis demonstrating DNA laddering in frozen tissues of five meningiomas. MIB1 LI revealed a highly significant increase from classical through atypical to anaplastic meningiomas (P 0.0001); haemangiopericytomas and papillary meningiomas were well within the range of atypical meningiomas. IST indices rose with increasing malignancy and correlated with MIB1 LI (P 0.0001); they showed a weak inverse correlation with BCL-2 immunoexpression (P= 0.05). BCL-2 expression tended to decrease with malignancy grade and was unrelated to MIB1 LI or frequency of apoptosis. Our data show that (i) apoptosis is a feature of meningiomas, significantly correlated with the malignancy scale, (ii) DNA fragmentation shows significant correlation with proliferation and inversely with BCL-2 expression; (iii) proliferation indices and frequencies of apoptosis/DNA fragmentation within meningioma subgroups corroborate the intermediate biological position of the atypical meningioma between classical and malignant meningiomas.     

经额底前纵裂入路显微手术切除巨大型嗅沟脑膜瘤

目的 探讨经额底前纵裂入路显微手术切除巨大型嗅沟脑膜瘤的手术方法及疗效.方法 回顾性分析2018年2月至2020年2月经额底前纵裂入路显微手术切除的10例巨大型嗅沟脑膜瘤的临床资料.结果 按Simpson手术切除标准分级:Simp-son分级Ⅰ级切除1例,Ⅱ级8例,Ⅲ级1例.无手术死亡病例,术后无颅内感染及癫痫等并发症...     

Low-grade supratentorial astrocytomas in adults: Management, immunohistochemical analysis and long-term follow-up

A retrospective review of supratentorial, low-grade astrocytomas in adults over a 10-year period (1983-1993) was performed. All 62 patients had computed tomography and surgery with histological and immunohistochemical analysis of the tumour. Radiotherapy was administered to all patients, regardless of the extent of surgical resection. Multivariate analysis showed that age of the patient at the time of surgery (P=0.008) and female sex (P=0.031) were the most important indicators of improved survival. No significant survival advantage was found with any particular symptom or symptom duration. Neither presence of a tumour cyst nor site of the tumour affected survival. Histological grading (St Anne-Mayo system) found 61 grade II astrocytomas (98%) and one grade I tumour. Six tumours (10%) were protoplasmic astrocytomas and 56 cases (90%) were diffuse fibrillary astrocytomas. Proliferation index derived from Ki-67 antibody staining and the presence of p53 protein expression were not significantly correlated with survival. Most patients underwent biopsy (79%) with 8% undergoing subtotal and 13% total resection. Increased extent of surgical removal showed a trend towards an improved survival (P=0.05). No survival advantage was found with increasing radiotherapy dose. Median survival in the study population was 5.1 years, with survival rates of 70% at 2 years and 53% at 5 years. The follow-up period ranged from 1 to 10.5 years. Younger age, female sex and the extent of surgical resection are important prognostic factors in the management of low-grade astrocytomas, whereas the efficacy of postoperative radiotherapy needs further evaluation. The prognostic significance of Ki-67 and p53 expression in low-grade astrocytomas remains to be determined.